Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.793
-0.063 (-7.39%)
Feb 24, 2025, 11:03 AM EST - Market open
Jaguar Health Revenue
Jaguar Health had revenue of $3.11M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $10.48M, down -2.25% year-over-year. In the year 2023, Jaguar Health had annual revenue of $9.76M, down -18.36%.
Revenue (ttm)
$10.48M
Revenue Growth
-2.25%
P/S Ratio
0.37
Revenue / Employee
$213,878
Employees
49
Market Cap
9.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
JAGX News
- 5 days ago - Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Accesswire
- 6 days ago - Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 - Accesswire
- 11 days ago - Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Accesswire
- 18 days ago - Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference - Accesswire
- 21 days ago - Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 - Accesswire
- 26 days ago - Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO - Accesswire
- 4 weeks ago - Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025 - Accesswire
- 6 weeks ago - Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Accesswire